Skip to main content

Loading market data...

BIO

Bio-Rad Laboratories, Inc.

NYSE • United states

$355.73

+$2.91

(+0.82%)

Source: Yahoo Finance · Quote time Oct 20, 2026 17:48 GMT+0000

Management
Credibility
Score

Bio-Rad Laboratories, Inc. (BIO)

Unavailable

Quotes may be delayed

$9.51B

Market Cap

99,344

Volume

42.8

P/E Ratio

Unavailable

Div Yield

Bio-Rad Laboratories, Inc. Price Chart

Loading price history…

Management Credibility Analysis

Unavailable

Verified Management Score Unavailable

Management credibility requires sourced guidance and earnings history.

Upcoming Catalysts

Verified event feed

Verified Catalysts Unavailable

No sourced upcoming event feed is configured for this stock yet.

Company profile

No description available

Chief executive: Not disclosed
Headquarters: 1000 ALFRED NOBEL DRIVE, HERCULES, CA
Founded: Not disclosed

📈 Company Timeline

Major business events

Positive

Negative

Neutral

4 Aug 2026

Bio-Rad Laboratories, Inc. filed Form 10-Q

Bio-Rad Laboratories, Inc. submitted Form 10-Q to the SEC for the period ending Jun 30, 2026.

4 Aug 2026

Bio-Rad Laboratories, Inc. reported Operating or financial results

Bio-Rad Laboratories, Inc. filed an 8-K covering operating or financial results, exit or restructuring costs, Regulation FD disclosure, supporting financial statements or exhibits.

30 Apr 2026

Bio-Rad Laboratories, Inc. securities registration filing

Bio-Rad Laboratories, Inc. filed a registration or prospectus document concerning securities.

30 Apr 2026

Bio-Rad Laboratories, Inc. filed Form 10-Q

Bio-Rad Laboratories, Inc. submitted Form 10-Q to the SEC for the period ending Mar 31, 2026.

30 Apr 2026

Bio-Rad Laboratories, Inc. reported Operating or financial results

Bio-Rad Laboratories, Inc. filed an 8-K covering operating or financial results, Regulation FD disclosure, supporting financial statements or exhibits.

Capital Structure & Financial Position

Financial strength and liquidity analysis

Cash and equivalents (USD)$517.00M

Total assets (USD)$10.25B

Total liabilities (USD)$3.08B

Shareholders' equity (USD)$7.17B

Long-term debt (USD)$803.00M

Debt due within a year (USD)$200,000

Source: SEC EDGAR company facts (opens in a new tab) Balance sheet dated 30 Jun 2026

Peer Comparison - Industrials

Company	Price	Market Cap
TSLA - Tesla, Inc.	$386.47 Yahoo Finance	$1.53T
CAT - Caterpillar Inc.	$733.82 Yahoo Finance	$337.32B
RTX - RTX Corporation	$193.79 Yahoo Finance	$261.18B
TMO - Thermo Fisher Scientific Inc.	$694.02 Yahoo Finance	$256.61B
UNP - Union Pacific Corporation	$289.49 Yahoo Finance	$171.98B

📋 Corporate Actions

Recent and upcoming corporate events

Verified Corporate Actions Unavailable

Dividend, buyback, split, and spin-off feeds are not ingested for this stock yet.

Financials

Financial statements and key metrics analysis

Quarter	Revenue (USD)	Operating income	Net income	Diluted EPS (USD)	Filed
Q2 2026	$651.00M	$72.60M	$371.40M	$13.85	10-Q · 4 Aug 2026
Q1 2026	$592.10M	$34.10M	−$527.10M	−$19.55	10-Q · 30 Apr 2026
Q4 2025	$693.20M	−$118.90M	$720.00M	Unavailable	10-K · 13 Feb 2026
Q3 2025	$653.00M	$65.30M	−$341.90M	−$12.70	10-Q · 29 Oct 2025
Q2 2025	$651.60M	$77.10M	$317.80M	$11.67	10-Q · 31 Jul 2025
Q1 2025	$585.40M	$23.70M	$64.00M	$2.29	10-Q · 1 May 2025

Source: SEC EDGAR company facts (opens in a new tab)

Analyst Consensus

Buy

Target: $360.00

1.2% upside potential

📈

Strong Buy

Unavailable

👍

Buy

1

⏸️

Hold

1

📉

Sell

0

2 analysts covering this stock

Source: Nasdaq analyst research (opens in a new tab) Retrieved 20 Oct 2026, 17:49 UTC Targets range 330.00–390.00 Ratings are third-party opinions, not advice.

💰 Upcoming Dividends

Next dividend payments

Verified Dividend Data Unavailable

Dividend calendar data is not ingested for this stock yet.

Guidance Evolution

Verified Guidance History Unavailable

Verified company guidance history is not ingested for this stock yet.

💼 Director Transactions

Recent insider activity

6

Sep 2026

Allison Schwartz

Director

Option exercise

Unavailable per share

92 shares

6

Sep 2026

Allison Schwartz

Director

Tax withholding

$386.11 per share

34 shares

6

Sep 2026

BARRY JAMES

EVP, President, LSG

Option exercise

Unavailable per share

1,056 shares

6

Sep 2026

BARRY JAMES

EVP, President, LSG

Tax withholding

$386.11 per share

470 shares

6

Sep 2026

EVRAN SEDAT

EVP, Global Supply Chain

Option exercise

Unavailable per share

864 shares

6

Sep 2026

EVRAN SEDAT

EVP, Global Supply Chain

Tax withholding

$386.11 per share

277 shares

6

Sep 2026

ENGELHARDT EVA ANETTE

EVP, President, CDG

Option exercise

Unavailable per share

1,152 shares

6

Sep 2026

ENGELHARDT EVA ANETTE

EVP, President, CDG

Tax withholding

$386.11 per share

485 shares

6

Sep 2026

ENLOE COURTNEY C

EVP, General Counsel & Sec

Option exercise

Unavailable per share

768 shares

6

Sep 2026

ENLOE COURTNEY C

EVP, General Counsel & Sec

Tax withholding

$386.11 per share

305 shares

Top Shareholders

First Eagle Investment Management, Llc

2,606,219 shares

0.132% change

6/30/2026

Vanguard Group Inc

1,774,263 shares

-1.075% change

12/31/2025

Blackrock, Inc.

1,698,929 shares

1.123% change

6/30/2026

Dimensional Fund Advisors Lp

944,548 shares

-13.29% change

6/30/2026

Vanguard Capital Management Llc

826,972 shares

-0.504% change

6/30/2026

Ariel Investments, Llc

816,751 shares

3.917% change

6/30/2026

Vanguard Portfolio Management Llc

816,198 shares

-1.566% change

6/30/2026

Earnest Partners Llc

580,752 shares

-1.355% change

6/30/2026

State Street Corp

571,762 shares

2.179% change

6/30/2026

Bank Of America Corp /De/

490,412 shares

10.216% change

6/30/2026

Source: Nasdaq institutional holdings (opens in a new tab) Observed 20 Oct 2026, 17:49 UTC· 1 day ago

Research coverage and investment tools

Bio-Rad Laboratories, Inc. (BIO) is a stock listed on the New York Stock Exchange in the United States, in the Industrials sector (Biotechnology: Laboratory Analytical Instruments). Its last price was US$355.73 on 20 Oct 2026. That is 75% of the way from its 52-week low of US$236.73 to its 52-week high of US$396.23. Its market capitalisation was US$9.51 billion at that price.

Watch Add to portfolio Set an alert Compare Position size

How position sizing works Dividend yield and total return

Quarter	Revenue	Operating income	Net income	Diluted EPS	Gross margin	Operating margin	Free cash flow	Filed
Q2 2026	$651.00M	$72.60M	$371.40M	$13.85	53.1%	11.2%	$66.70M	10-Q · 4 Aug 2026 (opens in a new tab)
Q1 2026	$592.10M	$34.10M	−$527.10M	−$19.55	52.3%	5.8%	$78.10M	10-Q · 30 Apr 2026 (opens in a new tab)
Q4 2025	$693.20M	−$118.90M	$720.00M	Unavailable	49.8%	-17.2%	$119.10M	10-K · 13 Feb 2026 (opens in a new tab)
Q3 2025	$653.00M	$65.30M	−$341.90M	−$12.70	52.6%	10.0%	$89.20M	10-Q · 29 Oct 2025 (opens in a new tab)
Q2 2025	$651.60M	$77.10M	$317.80M	$11.67	53.0%	11.8%	$70.80M	10-Q · 31 Jul 2025 (opens in a new tab)
Q1 2025	$585.40M	$23.70M	$64.00M	$2.29	52.3%	4.0%	$95.50M	10-Q · 1 May 2025 (opens in a new tab)

Cash and equivalents: $517.00M
Total assets: $10.25B
Total liabilities: $3.08B
Shareholders' equity: $7.17B
Long-term debt: $803.00M
Debt due within a year: $200,000

10-Q · 4 Aug 2026

Bio-Rad Laboratories, Inc. filed Form 10-Q (opens in a new tab)

Bio-Rad Laboratories, Inc. submitted Form 10-Q to the SEC for the period ending Jun 30, 2026.
8-K · 4 Aug 2026

Bio-Rad Laboratories, Inc. reported Operating or financial results (opens in a new tab)

Bio-Rad Laboratories, Inc. filed an 8-K covering operating or financial results, exit or restructuring costs, Regulation FD disclosure, supporting financial statements or exhibits.
S-8 · 30 Apr 2026

Bio-Rad Laboratories, Inc. securities registration filing (opens in a new tab)

Bio-Rad Laboratories, Inc. filed a registration or prospectus document concerning securities.
10-Q · 30 Apr 2026

Bio-Rad Laboratories, Inc. filed Form 10-Q (opens in a new tab)

Bio-Rad Laboratories, Inc. submitted Form 10-Q to the SEC for the period ending Mar 31, 2026.
8-K · 30 Apr 2026

Bio-Rad Laboratories, Inc. reported Operating or financial results (opens in a new tab)

Bio-Rad Laboratories, Inc. filed an 8-K covering operating or financial results, Regulation FD disclosure, supporting financial statements or exhibits.

Insider	Date	Transaction	Shares	Average price	Filing
Allison Schwartz Director	6 Sep 2026	Option exercise (M)	+92	—	Form 4 (opens in a new tab)
Allison Schwartz Director	6 Sep 2026	Tax withholding (F)	−34	$386.11	Form 4 (opens in a new tab)
BARRY JAMES EVP, President, LSG	6 Sep 2026	Option exercise (M)	+1,056	—	Form 4 (opens in a new tab)
BARRY JAMES EVP, President, LSG	6 Sep 2026	Tax withholding (F)	−470	$386.11	Form 4 (opens in a new tab)
EVRAN SEDAT EVP, Global Supply Chain	6 Sep 2026	Option exercise (M)	+864	—	Form 4 (opens in a new tab)
EVRAN SEDAT EVP, Global Supply Chain	6 Sep 2026	Tax withholding (F)	−277	$386.11	Form 4 (opens in a new tab)
ENGELHARDT EVA ANETTE EVP, President, CDG	6 Sep 2026	Option exercise (M)	+1,152	—	Form 4 (opens in a new tab)
ENGELHARDT EVA ANETTE EVP, President, CDG	6 Sep 2026	Tax withholding (F)	−485	$386.11	Form 4 (opens in a new tab)
ENLOE COURTNEY C EVP, General Counsel & Sec	6 Sep 2026	Option exercise (M)	+768	—	Form 4 (opens in a new tab)
ENLOE COURTNEY C EVP, General Counsel & Sec	6 Sep 2026	Tax withholding (F)	−305	$386.11	Form 4 (opens in a new tab)

Institution	Report date	Shares	Change
First Eagle Investment Management, Llc	6/30/2026	2,606,219	0.132%
Vanguard Group Inc	12/31/2025	1,774,263	-1.075%
Blackrock, Inc.	6/30/2026	1,698,929	1.123%
Dimensional Fund Advisors Lp	6/30/2026	944,548	-13.29%
Vanguard Capital Management Llc	6/30/2026	826,972	-0.504%
Ariel Investments, Llc	6/30/2026	816,751	3.917%
Vanguard Portfolio Management Llc	6/30/2026	816,198	-1.566%
Earnest Partners Llc	6/30/2026	580,752	-1.355%
State Street Corp	6/30/2026	571,762	2.179%
Bank Of America Corp /De/	6/30/2026	490,412	10.216%

Previous close: 352.82 USD
Day range: 351.11 – 356.75 USD
52-week range: 236.73 – 396.23 USD
Volume: 99,344
Market cap: $9.51B
Average volume: 232,100
P/E ratio: 42.8
EPS (FY 2025, diluted): 27.85 USD
Shares outstanding: 26.74M
Beta (5Y monthly): 1.06

Price, ranges and volume: Yahoo Finance (opens in a new tab) Observed 20 Oct 2026, 17:48 UTC· 1 day ago

Average volume and shares: Nasdaq (opens in a new tab) Observed 22 Oct 2026, 01:36 UTC· 4 hours ago

P/E is market cap ÷ trailing 12-month net income from SEC filings.

EPS: SEC EDGAR company facts (opens in a new tab)

Beta: 5 years of monthly returns against the S&P 500, calculated from Yahoo Finance prices. Market cap is the price × shares outstanding.

This research is not available for BIO yet

Guidance history

IMPORTANT FINANCIAL DISCLAIMER: The information provided on this platform is for educational and informational purposes only and should not be construed as investment advice. All investments involve risk, including potential loss of principal. Past performance does not guarantee future results. Take Profits is not a registered investment advisor and does not provide personalized investment advice. Users should conduct their own research and consult with qualified financial professionals before making investment decisions. Market data may be delayed and is provided by third-party sources.